Key mechanisms of acquired resistance to combination BRAF inhibitor and MEK inhibitor therapy include mutations in MEK and NRAS25; however, it is unknown whether cells expressing these mutations are pre-existing in the tumor or the mutations occur de novo. Here, BRAF is linked to neoplasm.